Literature DB >> 20163277

Ertapenem.

Blaise L Congeni1.   

Abstract

IMPORTANCE OF THE FIELD: Given their broad-spectrum and safety, carbapenems are a widely used class of antibiotics, especially in the treatment of hospital-acquired infections including infections due to multidrug-resistant organisms. Ertapenem is a unique member of this class, with a narrower spectrum that lacks reliable activity against Pseudomonas and Enterococcus. Given its spectrum and half-life of 4 h it is better suited to use in community-acquired infections and it is particularly well positioned for use in the outpatient setting. AREAS COVERED IN THIS REVIEW: Chemistry, mechanism of action, pharmacokinetics/pharmacodynamics, safety and indications for use will be covered in this review. Similar to other beta-lactams, the carbapenems inhibit cell wall synthesis by binding to and inhibiting penicillin-binding proteins. Their resistance to beta-lactamases including AmpC and extended-spectrum beta-lactamases enhances their usefulness. Similar to other beta-lactams, ertapenem exhibits time-dependent killing. Given this profile, ertapenem has been found to be useful in intra-abdominal infections, acute pelvic infections, complicated skin and skin structure infections, community-acquired pneumonia and complicated urinary tract infections. WHAT THE READER WILL GAIN: This review will enable the reader to understand differences between the different carbapenems, especially with regard to ertapenem. Once an understanding is gained with regard to pharmacology and microbiology, the reader will be positioned to understand better those circumstances in which use of ertapenem should be considered. TAKE HOME MESSAGE: Substantial differences between the carbapenems exist. Ertapenem has unique characteristics that may make it useful in specific clinical circumstances that are detailed in this review.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20163277     DOI: 10.1517/14656561003631397

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN: 1465-6566            Impact factor:   3.889


  7 in total

Review 1.  Emergence of multidrug-resistant, extensively drug-resistant and untreatable gonorrhea.

Authors:  Magnus Unemo; Robert A Nicholas
Journal:  Future Microbiol       Date:  2012-12       Impact factor: 3.165

2.  In vitro activity of ertapenem versus ceftriaxone against Neisseria gonorrhoeae isolates with highly diverse ceftriaxone MIC values and effects of ceftriaxone resistance determinants: ertapenem for treatment of gonorrhea?

Authors:  Magnus Unemo; Daniel Golparian; Athena Limnios; David Whiley; Makoto Ohnishi; Monica M Lahra; John W Tapsall
Journal:  Antimicrob Agents Chemother       Date:  2012-04-30       Impact factor: 5.191

3.  Antibacterial and Antibiofilm Potency of XF Drugs, Impact of Photodynamic Activation and Synergy With Antibiotics.

Authors:  Emma Louise Board-Davies; William Rhys-Williams; Daniel Hynes; David Williams; Damian Joseph John Farnell; William Love
Journal:  Front Cell Infect Microbiol       Date:  2022-06-30       Impact factor: 6.073

4.  In Vitro Activities of Novel Antimicrobial Combinations against Extensively Drug-Resistant Acinetobacter baumannii.

Authors:  J Córdoba; N M Coronado-Álvarez; D Parra; J Parra-Ruiz
Journal:  Antimicrob Agents Chemother       Date:  2015-09-14       Impact factor: 5.191

5.  Model-Informed Drug Development, Pharmacokinetic/Pharmacodynamic Cutoff Value Determination, and Antibacterial Efficacy of Benapenem against Enterobacteriaceae.

Authors:  Xi-Wei Ji; Feng Xue; Zi-Sheng Kang; Wei Zhong; Isabelle Hui-San Kuan; Xi-Ping Yang; Xiao Zhu; Yun Li; Yuan Lv
Journal:  Antimicrob Agents Chemother       Date:  2020-02-21       Impact factor: 5.191

6.  In Vitro Activity of Ertapenem against Neisseria gonorrhoeae Clinical Isolates with Decreased Susceptibility or Resistance to Extended-Spectrum Cephalosporins in Nanjing, China (2013 to 2019).

Authors:  Xuechun Li; Wenjing Le; Xiangdi Lou; Caroline A Genco; Peter A Rice; Xiaohong Su
Journal:  Antimicrob Agents Chemother       Date:  2022-05-02       Impact factor: 5.938

7.  Carbapenem stewardship with ertapenem and antimicrobial resistance-a scoping review.

Authors:  Tiago Zequinão; João Paulo Telles; Juliano Gasparetto; Felipe Francisco Tuon
Journal:  Rev Soc Bras Med Trop       Date:  2020-11-06       Impact factor: 1.581

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.